FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
Aleksandra GruslovaBryan McClellanHenriette U BalindaSuryavathi ViswanadhapalliVictoria AlersGangadhara R SareddyTim HuangMichael GarciaLinda deGraffenriedRatna K VadlamudiAndrew J BrennerPublished in: Breast cancer research and treatment (2021)
Our preclinical data provide evidence that FASN inhibition by TVB-3166 presents a promising therapeutic strategy for the treatment of endocrine-resistant breast cancer. Further clinical development of FASN inhibitors for endocrine-resistant breast cancer should be considered.
Keyphrases